Antisoma
Trial failures threaten UK biotech
February 18, 2011Research and Development AML, AS1411, AS1413, Antisoma, Juvista, Renovo, UK biotech, acute myeloid leukaemia, anti-scarring, biotech
A number of late stage failures from British biotech firms have left a looming question mark over the future of …
Novartis drops late stage lung cancer candidate
November 11, 2010Research and Development ASA404, Antisoma, NSCLC, Novartis, cancer research, lung cancer, non small cell lung cancer, non-small cell lung cancer
Novartis has discontinued phase III trials for its lung cancer candidate ASA404 after it once again failed to meet its …
Antisoma stages comeback with promising cancer drugs
May 20, 2010Research and Development AML, Antisoma, chemotherapy, leukaemia
UK biotech Antisoma is looking to put previous late-stage trial failures behind it by focusing on two new cancer drugs. …
Antisoma cancer drug fails in phase III
March 29, 2010Research and Development Antisoma, NSCLC, lung cancer
UK biotech Antisoma has suffered a disappointing late-stage failure with a potential lung cancer treatment it was developing with Novartis. …
